4D Molecular Therapeutics IncNASDAQ:FDMT
- LAST PRICE7.8000
- TODAY'S CHANGE (%)-0.0700 (-0.8895%)
- Bid / Lots7.7900/ 12
- Ask / Lots7.8200/ 4
- Open / Previous Close7.8700 / 7.8700
- Day Range
- 52 Week Range
- Volume155,480
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FDMT |
|---|---|---|
| 09:32 ET | 12145 | 7.87 |
| 09:33 ET | 1200 | 7.87 |
| 09:35 ET | 2002 | 7.865 |
| 09:37 ET | 14550 | 7.8 |
| 09:39 ET | 2001 | 7.76 |
| 09:42 ET | 4556 | 7.675 |
| 09:44 ET | 1618 | 7.68 |
| 09:46 ET | 1100 | 7.655 |
| 09:48 ET | 5313 | 7.64 |
| 09:50 ET | 400 | 7.64 |
| 09:51 ET | 6897 | 7.65 |
| 09:53 ET | 5568 | 7.56 |
| 09:55 ET | 2720 | 7.55 |
| 09:57 ET | 5263 | 7.56 |
| 10:00 ET | 4588 | 7.53 |
| 10:02 ET | 6645 | 7.62 |
| 10:04 ET | 4806 | 7.605 |
| 10:06 ET | 15397 | 7.653 |
| 10:08 ET | 1800 | 7.76 |
| 10:09 ET | 1500 | 7.73 |
| 10:11 ET | 371 | 7.77 |
| 10:13 ET | 500 | 7.84 |
| 10:15 ET | 600 | 7.825 |
| 10:18 ET | 1400 | 7.79 |
| 10:20 ET | 2444 | 7.805 |
| 10:22 ET | 227 | 7.79 |
| 10:24 ET | 993 | 7.8072 |
| 10:26 ET | 227 | 7.77 |
| 10:27 ET | 300 | 7.8 |
| 10:29 ET | 100 | 7.78 |
| 10:31 ET | 3358 | 7.83 |
| 10:33 ET | 1510 | 7.8 |
| 10:36 ET | 1885 | 7.74 |
| 10:38 ET | 100 | 7.75 |
| 10:40 ET | 768 | 7.745 |
| 10:42 ET | 1078 | 7.765 |
| 10:44 ET | 300 | 7.78 |
| 10:51 ET | 1180 | 7.825 |
| 10:54 ET | 1001 | 7.77 |
| 10:56 ET | 200 | 7.78 |
| 11:00 ET | 552 | 7.78 |
| 11:02 ET | 500 | 7.77 |
| 11:03 ET | 500 | 7.78 |
| 11:05 ET | 200 | 7.76 |
| 11:07 ET | 283 | 7.765 |
| 11:12 ET | 500 | 7.79 |
| 11:14 ET | 114 | 7.77 |
| 11:16 ET | 200 | 7.76 |
| 11:18 ET | 825 | 7.76 |
| 11:20 ET | 5407 | 7.775 |
| 11:21 ET | 900 | 7.8 |
| 11:23 ET | 125 | 7.8 |
Nov 21, 2024
DJ 4D Molecular Therapeutics Initiated at Underweight by Morgan Stanley, from 6:34AM ET on Thursday Nov 21, 2024 by Dow Jones
6:34AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 14, 2024
DJ 4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital, from 4:54PM ET on Thursday Nov 14, 2024 by Dow Jones
4:54PM ET on Thursday Nov 14, 2024 by Dow JonesDJ 4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co., from 1:41PM ET on Thursday Nov 14, 2024 by Dow Jones
1:41PM ET on Thursday Nov 14, 2024 by Dow JonesDJ 4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital, from 12:04PM ET on Thursday Nov 14, 2024 by Dow Jones
12:04PM ET on Thursday Nov 14, 2024 by Dow Jones4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
4D Molecular Therapeutics Inc | 346.7M | -2.8x | --- |
AC Immune SA | 332.4M | -7.3x | --- |
C4 Therapeutics Inc | 295.8M | -2.7x | --- |
TScan Therapeutics Inc | 269.5M | -4.4x | --- |
Uniqure NV | 294.9M | -1.2x | --- |
Iteos Therapeutics Inc | 312.0M | -2.7x | --- |
Company Information
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Contact Information
- Headquarters
- 5858 Horton Street #455, EmeryvilleEMERYVILLE, CA, United States 94608
- Phone
- 510-505-2680
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- John Milligan
- President, Chief Operating Officer
- Fariborz Kamal
- Chief Executive Officer, Co-Founder, Director
- David Kirn
- Chief Financial and Business Officer
- Uneek Mehra
- Chief Medical Officer
- Robert Kim
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $346.7M |
|---|---|
Revenue (TTM) | $18.0K |
Shares Outstanding | 46.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.75 |
EPS | $-2.76 |
Book Value | $7.15 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 19,261.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -935,416.70% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
